{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T21:18:06Z","timestamp":1776719886629,"version":"3.51.2"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T00:00:00Z","timestamp":1546041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,14]]},"DOI":"10.1093\/carcin\/bgy184","type":"journal-article","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T04:18:51Z","timestamp":1545970731000},"page":"412-421","source":"Crossref","is-referenced-by-count":31,"title":["Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells"],"prefix":"10.1093","volume":"40","author":[{"given":"Preethi","family":"Ravindranathan","sequence":"first","affiliation":[{"name":"Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute, and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Pasham","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott and White Research Institute, and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"key":"2019051404394040000_CIT0001","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/jmf.2012.0170","article-title":"Use of grape polyphenols against carcinogenesis: putative molecular mechanisms of action using in vitro and in vivo test systems","volume":"16","author":"Gollucke","year":"2013","journal-title":"J. Med. Food"},{"key":"2019051404394040000_CIT0002","first-page":"1877","article-title":"Activities of tannins\u2014from in vitro studies to clinical trials","volume":"10","author":"Sieniawska","year":"2015","journal-title":"Nat. Prod. Commun."},{"key":"2019051404394040000_CIT0003","doi-asserted-by":"crossref","first-page":"24673","DOI":"10.3390\/ijms161024673","article-title":"Bioactive compounds and antioxidant activity in different types of berries","volume":"16","author":"Skrovankova","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"2019051404394040000_CIT0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nut.2013.04.007","article-title":"Edible berries: bioactive components and their effect on human health","volume":"30","author":"Nile","year":"2014","journal-title":"Nutrition"},{"key":"2019051404394040000_CIT0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/01635581.2011.607549","article-title":"An overview of cancer chemopreventive potential and safety of proanthocyanidins","volume":"63","author":"Ou\u00e9draogo","year":"2011","journal-title":"Nutr. Cancer"},{"key":"2019051404394040000_CIT0006","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1158\/1078-0432.CCR-06-1465","article-title":"Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells","volume":"12","author":"Kaur","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"2019051404394040000_CIT0007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/carcin\/bgy034","article-title":"Mechanistic insights into anticancer properties of oligomeric proanthocyanidins from grape seeds in colorectal cancer","volume":"39","author":"Ravindranathan","year":"2018","journal-title":"Carcinogenesis"},{"key":"2019051404394040000_CIT0008","doi-asserted-by":"crossref","first-page":"13869","DOI":"10.1038\/s41598-018-32267-8","article-title":"A combination of curcumin and oligomeric proanthocyanidins offer superior anti-tumorigenic properties in colorectal cancer","volume":"8","author":"Ravindranathan","year":"2018","journal-title":"Sci. Rep."},{"key":"2019051404394040000_CIT0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"2019051404394040000_CIT0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","article-title":"Mechanisms of chemoresistance in cancer stem cells","volume":"2","author":"Abdullah","year":"2013","journal-title":"Clin. Transl. Med."},{"key":"2019051404394040000_CIT0011","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0923-2508(01)01201-3","article-title":"ABC transporters catalyzing carbohydrate uptake","volume":"152","author":"Schneider","year":"2001","journal-title":"Res. Microbiol."},{"key":"2019051404394040000_CIT0012","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2407-5-78","article-title":"Cancer cell adaptation to chemotherapy","volume":"5","author":"Di Nicolantonio","year":"2005","journal-title":"BMC Cancer"},{"key":"2019051404394040000_CIT0013","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(05)63876-7","article-title":"Multidrug resistance protein in recurrent breast cancer","volume":"349","author":"Nooter","year":"1997","journal-title":"Lancet"},{"key":"2019051404394040000_CIT0014","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.critrevonc.2015.05.012","article-title":"The role of ABC transporters in ovarian cancer progression and chemoresistance","volume":"96","author":"Ween","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2019051404394040000_CIT0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP-dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"2019051404394040000_CIT0016","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.20831","article-title":"Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma","volume":"115","author":"K\u00f6nig","year":"2005","journal-title":"Int. J. Cancer"},{"key":"2019051404394040000_CIT0017","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-004-0653-9","article-title":"Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications","volume":"131","author":"Berger","year":"2005","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"2019051404394040000_CIT0018","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.1987.5.4.641","article-title":"Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients","volume":"5","author":"Ozols","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"2019051404394040000_CIT0019","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0959-8049(96)00091-3","article-title":"Clinical trials of P-glycoprotein reversal in solid tumours","volume":"32A","author":"Ferry","year":"1996","journal-title":"Eur. J. Cancer"},{"key":"2019051404394040000_CIT0020","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cncr.21666","article-title":"Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar\/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group","volume":"106","author":"Friedenberg","year":"2006","journal-title":"Cancer"},{"key":"2019051404394040000_CIT0021","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/blood.V100.4.1224.h81602001224_1224_1232","article-title":"Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720","volume":"100","author":"Baer","year":"2002","journal-title":"Blood"},{"key":"2019051404394040000_CIT0022","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/gyno.2002.6762","article-title":"A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy","volume":"86","author":"Seiden","year":"2002","journal-title":"Gynecol. Oncol."},{"key":"2019051404394040000_CIT0023","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/cncr.22492","article-title":"A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer","volume":"109","author":"Gandhi","year":"2007","journal-title":"Cancer"},{"key":"2019051404394040000_CIT0024","first-page":"3710","article-title":"A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies","volume":"8","author":"Rubin","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"2019051404394040000_CIT0025","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1158\/1078-0432.CCR-10-1725","article-title":"A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer","volume":"17","author":"Kelly","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"2019051404394040000_CIT0026","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1038\/s41598-018-21478-8","article-title":"Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer","volume":"8","author":"Toden","year":"2018","journal-title":"Sci. Rep."},{"key":"2019051404394040000_CIT0027","first-page":"895","article-title":"FLEXBAR\u2014flexible barcode and adapter processing for next-generation sequencing platforms","volume":"1","author":"Dodt","year":"2012","journal-title":"Biology (Basel)."},{"key":"2019051404394040000_CIT0028","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1101\/gr.135350.111","article-title":"GENCODE: the reference human genome annotation for The ENCODE Project","volume":"22","author":"Harrow","year":"2012","journal-title":"Genome Res."},{"key":"2019051404394040000_CIT0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","article-title":"HISAT: a fast spliced aligner with low memory requirements","volume":"12","author":"Kim","year":"2015","journal-title":"Nat. Methods"},{"key":"2019051404394040000_CIT0030","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"2019051404394040000_CIT0031","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq\u2014a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"key":"2019051404394040000_CIT0032","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"2019051404394040000_CIT0033","author":"Dewey","year":"2017"},{"key":"2019051404394040000_CIT0034","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/13543784.2012.679339","article-title":"Investigational ABC transporter inhibitors","volume":"21","author":"Falasca","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2019051404394040000_CIT0035","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s11095-005-6810-2","article-title":"Apical\/basolateral surface expression of drug transporters and its role in vectorial drug transport","volume":"22","author":"Ito","year":"2005","journal-title":"Pharm. Res."},{"key":"2019051404394040000_CIT0036","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","article-title":"P-glycoprotein: from genomics to mechanism","volume":"22","author":"Ambudkar","year":"2003","journal-title":"Oncogene"},{"key":"2019051404394040000_CIT0037","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.3390\/ijms18091892","article-title":"Critical role of the human ATP-binding cassette G1 transporter in cardiometabolic diseases","volume":"18","author":"Hardy","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2019051404394040000_CIT0038","doi-asserted-by":"crossref","first-page":"115803","DOI":"10.18632\/oncotarget.23253","article-title":"Dishevelled1-3 contribute to multidrug resistance in colorectal cancer via activating Wnt\/\u03b2-catenin signaling","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"2019051404394040000_CIT0039","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2559.2008.03026.x","article-title":"Expression and localization of ATP binding cassette (ABC) family of drug transporters in gastric hepatoid adenocarcinomas","volume":"52","author":"Kamata","year":"2008","journal-title":"Histopathology"},{"key":"2019051404394040000_CIT0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.canlet.2018.04.013","article-title":"ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2","volume":"427","author":"Luo","year":"2018","journal-title":"Cancer Lett."},{"key":"2019051404394040000_CIT0041","doi-asserted-by":"crossref","first-page":"34617","DOI":"10.18632\/oncotarget.16119","article-title":"Usefulness of the MRP2 promoter to overcome the chemoresistance of gastrointestinal and liver tumors by enhancing the expression of the drug transporter OATP1B1","volume":"8","author":"Herraez","year":"2017","journal-title":"Oncotarget"},{"key":"2019051404394040000_CIT0042","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/sj.bjc.6606071","article-title":"Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma","volume":"104","author":"Yamasaki","year":"2011","journal-title":"Br. J. Cancer"},{"key":"2019051404394040000_CIT0043","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-4274(02)00497-6","article-title":"The role of multidrug transporters in drug availability, metabolism and toxicity","volume":"140-141","author":"Bod\u00f3","year":"2003","journal-title":"Toxicol. Lett."},{"key":"2019051404394040000_CIT0044","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2174\/138161206775201965","article-title":"An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy","volume":"12","author":"Takara","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"2019051404394040000_CIT0045","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.coph.2006.01.009","article-title":"Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer","volume":"6","author":"Modok","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"2019051404394040000_CIT0046","doi-asserted-by":"crossref","first-page":"99901","DOI":"10.18632\/oncotarget.21914","article-title":"PD-1\/PD-L1 interaction up-regulates MDR1\/P-gp expression in breast cancer cells via PI3K\/AKT and MAPK\/ERK pathways","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"2019051404394040000_CIT0047","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/j.1460-2075.1983.tb01543.x","article-title":"P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts","volume":"2","author":"Rotter","year":"1983","journal-title":"EMBO J."},{"issue":"23 Pt 1","key":"2019051404394040000_CIT0048","first-page":"6304","article-title":"Participation of p53 protein in the cellular response to DNA damage","volume":"51","author":"Kastan","year":"1991","journal-title":"Cancer Res."},{"key":"2019051404394040000_CIT0049","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1101\/gad.7.4.535","article-title":"Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis","volume":"7","author":"Lowe","year":"1993","journal-title":"Genes Dev."},{"key":"2019051404394040000_CIT0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"2019051404394040000_CIT0051","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport\u2014an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"key":"2019051404394040000_CIT0052","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1567201043480036","article-title":"The role of ABC transporters in drug resistance, metabolism and toxicity","volume":"1","author":"Glavinas","year":"2004","journal-title":"Curr. Drug Deliv."},{"key":"2019051404394040000_CIT0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-398339-8.00001-X","article-title":"Membrane transporters in drug development","volume":"63","author":"Keogh","year":"2012","journal-title":"Adv. Pharmacol."},{"key":"2019051404394040000_CIT0054","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1021\/mp3003144","article-title":"Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar","volume":"9","author":"Durmus","year":"2012","journal-title":"Mol. Pharm."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/40\/3\/412\/28639437\/bgy184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T10:48:36Z","timestamp":1605869316000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article\/40\/3\/412\/5266693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,29]]},"references-count":54,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,12,29]]},"published-print":{"date-parts":[[2019,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgy184","relation":{},"ISSN":["0143-3334","1460-2180"],"issn-type":[{"value":"0143-3334","type":"print"},{"value":"1460-2180","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3]]},"published":{"date-parts":[[2018,12,29]]}}}